Alzheimer’s Study Results Were Foreseeable, Not Astonishing
A 20-year follow-up of the NIH-funded, 2,800-participant ACTIVE study reports that less than 23 hours of speed-of-processing training delivered...
Aprea’s WEE1 Inhibitor Shows Surging, Positive Trial Data
Aprea reported a 50% reduction in target lesions at first assessment and an 87% drop in CA-125 (362 to...
TScan Completes Trial Enrollment, FDA Clears New Heme Drugs
Patients who fail to reach complete donor chimerism by month two after allogeneic transplant face a markedly higher relapse...
Aardvark Announces Voluntary Pause of Phase 3 HERO Trial
Aardvark Therapeutics has halted enrollment and dosing in its Phase 3 HERO trial and its open-label extension after reversible...
Cogent Highlights Bezuclastinib Summit Trial Data at AAAAI
Bezuclastinib delivered a mean −32.0-point reduction in total symptom score at 48 weeks in NonAdvanced systemic mastocytosis, a 56%...
First Participants Dosed in Scynexis’s SCY-247 Phase 1 Trial
SCYNEXIS has begun dosing in a Phase 1 single- and multiple-ascending dose study of its intravenous SCY-247, with initial...
Fractyl Trial Targets Post-GLP-1 Weight Maintenance
Fractyl Health has completed randomization in REMAIN-1, its sham-controlled pivotal cohort evaluating the Revita endoscopic procedure for weight maintenance...
First Patient Dosed in MindRank’s AI-Designed GLP-1 Trial
MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of its oral...
Ophirex Supplies Marimastat for Snakebite Treatment Study
Phase 2 platform funding of £4.2 million is backing TOCSINS, a multicountry trial evaluating oral snakebite therapies, with Ophirex...
MindRank’s Breakthrough AI GLP-1 Drug Enters Phase III Trial
MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of MDR-001, an...